A retropsective study evaluating efficacy of tocilizumab therapy for therapy-refractory uveitis associated with juvenile idiopathic arthritis (JIA)

Trial Profile

A retropsective study evaluating efficacy of tocilizumab therapy for therapy-refractory uveitis associated with juvenile idiopathic arthritis (JIA)

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Oct 2016

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Juvenile rheumatoid arthritis; Uveitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Oct 2016 New trial record
    • 15 Sep 2016 Results published in The Journal of Rheumatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top